21:29:38 EDT Mon 27 Mar 2023
Enter Symbol
or Name

Medivolve Inc (2)
Symbol MEDV
Shares Issued 27,019,248
Close 2023-01-19 C$ 0.155
Recent Sedar Documents

Medivolve arranges $4-million private placement

2023-01-19 19:07 ET - News Release

Mr. David Preiner reports


Medivolve Inc. has arranged a non-brokered private placement offering of common shares at a price of 15 cents per common share for aggregate gross proceeds of up to $4-million.

All securities issued in connection with the offering will be subject to a statutory hold period of four-months and one day. Completion of the offering is subject to a number of conditions, including final approval of the Neo Stock Exchange.

The company intends to use the net proceeds of the offering to advance Medivolve's business, marketing, repayment of outstanding debt and payables, and for general corporate purposes. The offering is expected to close on or about Jan. 31, 2023, and may close in tranches.

No finder fees are anticipated to be paid as part of the offering.

About Medivolve Inc.

Medivolve (NEO: MEDV, OTC: MEDVD and Frankfurt Stock Exchange: 4NC) is a health care technology company that seeks to reinvent the U.S. health care system by leveraging a bespoke telehealth platform, a clinical diagnostic network and a data-driven artificial intelligence framework to improve patient care.

The company was born out of the health care crisis: to rethink, relearn and ultimately reimagine a better way for the health care system to operate. Its network of retail collection sites play an important role in recovery by giving Americans access to fast, accurate and inexpensive clinical services when and where they need it. These centres will also play a pivotal role in diagnostic testing, vaccinations and other point-of-care services. The company is building disruptive technologies to make it easier and faster to identify, treat and prevent medical issues. In doing so, it is working to give patients a holistic and empowered view of their personal health.

Its long-term mission is to address systemic issues in the nation's fragmented, overly complex and expensive health care system. Medivolve's next phase of growth is about pivoting the model and putting the pieces together to build a profitable health technology company. The company is developing a singular, streamlined technology network to provide data-driven physician consultations, clinical diagnostics and prescription services. Its team is united by a powerful, singular purpose: harnessing the transformative power of technology to create healthier lives.

Underpinned by a bespoke, artificial-intelligence-driven platform, it is developing a system that constantly gets smarter, takes the guesswork out of diagnostics and flags critical health issues to help physicians, delivering a high level of personalization for each patient.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.